The primary objectives of this study is to identify a safe, tolerable dose of pentoxifylline
in children with cerebral malaria and to establish an acceptable pentoxifylline dosage
regimen for use in multi center Phase II and Phase III studies.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)